<DOC>
	<DOCNO>NCT00775125</DOCNO>
	<brief_summary>The primary objective determine effect steady-state DRV/rtv 600/100 mg twice daily ( b.i.d . ) steady-state pharmacokinetics telaprevir 750 mg every ( q ) 8h 1125 mg q12h vice versa ; - determine effect steady-state fAPV/rtv 700/100 mg b.i.d . steady-state pharmacokinetics telaprevir 750 mg q8h 1125 mg q 12h vice versa ; determine steady-state pharmacokinetics telaprevir 750 mg q8h versus telaprevir 1125 mg q12h , alone coadministration either steady-state DRV/rtv 600/100 mg b.i.d fAPV/rtv 700/100 mg b.i.d .</brief_summary>
	<brief_title>VX-950-TiDP24-C124 : A Phase I Trial Investigate Potential Pharmacokinetic Interactions Between Telaprevir Darunavir/Ritonavir Between Telaprevir Fosamprenavir/Ritonavir Steady-state .</brief_title>
	<detailed_description>This Phase I , open-label , randomize ( patient assign different treatment base chance ) , 2-way crossover trial 2 panel healthy subject investigate effect steady-state darunavir/ritonavir ( DRV/rtv ) 600/100 mg b.i.d . ( twice day ) fosamprenavir/ritonavir ( fAPV/rtv ) 700/100 mg b.i.d . steady state pharmacokinetics ( study bodily absorption , distribution , metabolism , excretion drug ) telaprevir 750 mg q 8h 1125 mg q12h , vice versa.Telaprevir investigate treatment HCV infection.The trial enroll 40 subject , divide 2 panel 20 subject . Subjects Panel 1 receive Treatments A B , subject Panel 2 receive Treatments C D , randomize order . In panel , treatment separate washout period least 13 day . In Panel 1 , Treatment A , subject receive telaprevir 750 mg q8h Days 1 10 , telaprevir 1125 mg q12h Days 11 13 morning dose Day 14 . In Panel 1 , Treatment B , subject receive DRV/rtv 600/100 mg b.i.d . Days 1 23 , additional morning dose Day 24 , coadministration telaprevir 750 mg q8h Days 11 20 , 1125 mg q12h Days 21 23 morning dose Day 24 . In Panel 2 , Treatment C , subject receive telaprevir 750 mg q 8h Days 1 10 , telaprevir 1125 mg q12h Days 11 13 morning dose Day 14 . In Panel 2 , Treatment D , subject receive fAPV/rtv 700/100 mg b.i.d . Days 1 23 , additional morning dose Day 24 , coadministration telaprevir 750 mg q8h Days 11 20 , 1125 mg q12h Days 21 23 morning dose Day 24 . All intake study medication feed condition . Pharmacokinetic profile telaprevir VRT-127394 ( Rdiastereomer telaprevir ) measure 8 hour intake morning dose Day 10 Treatments A C Day 20 Treatments B D , 12 hour intake morning dose Day 14 Treatments A C Day 24 Treatments B D. During Treatment B , pharmacokinetic profile DRV ritonavir measure 12 hour intake morning dose Day 10 , Day 20 Day 24 . During Treatment D , pharmacokinetic profile amprenavir ritonavir measure 12 hour intake morning dose Day 10 , Day 20 Day 24 . Safety tolerability evaluation record regular interval throughout trial period . Group A/C : telaprevir 750 mg 8 hrs Days 1-10 , telaprevir 1125 mg 12hrs Days 11-13 morning dose Day 14 . Group B : DRV/rtv 600/100 mg 2/day Days 1-23 + morning dose Day 24 + telaprevir 750 mg 8 hrs Days 11-20 , 1125 mg 12hrs Days 21 23 + morning dose Day 24 . Group D : fAPV/rtv 700/100 mg 2/day Days 1-23 + morning dose Day 24 , + telaprevir 750 mg 8hrs Days 11-20 , 1125 mg 12hrs Days 21-23 + morning dose Day 24 .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Females menopause least 3 year surgically sterilize Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior screen Normal weight screen define body mass index ( BMI ) 18 30 kg/m2 , extremes include Able comply protocol requirement Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , ECG , vital sign , result blood biochemistry , blood coagulation hematology test urinalysis carry screen . Subjects must history illness , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer trial drug ( ) subject Subjects currently use prescription medication . Subjects stop shortduration course prescription medication least 14 day screen visit . Potential subject stop chronic , prescribe medication take direction physician , without obtain agreement physician Subjects regular treatment overthecounter medication . Subjects stop overthecounter medication date screen visit le 7 day prior first administration study medication ( Day 1 Session I ) . Potential subject stop chronic , overthecounter medication take direction physician , without obtain agreement physician Subjects consumeherbal medication dietary supplement grapefruit grapefruit juice , apple juice , orange juice within 14 day first administration study medication ( Day 1 Session I ) Subjects history drug alcohol abuse addiction within 2 year prior dose , test positive alcohol drug amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opioids , metamphetamine methadone screening period Subject participate clinical study involve administration investigational drug within 3 month 5 half life ( whichever longer ) prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>VX-950-TiDP24-C124</keyword>
	<keyword>VX-950-C124</keyword>
	<keyword>HCV</keyword>
	<keyword>DDI</keyword>
	<keyword>telaprevir</keyword>
	<keyword>darunavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>steady-state</keyword>
</DOC>